ESTRO 2024 - Abstract Book

S1645

Clinical - Lung

ESTRO 2024

Keywords: GOECP-SEOR, POPULATION-BASED, TREATMENT PATTERNS.

References:

1. Lung Source: Globocan 2020 Number of new cases in 2020, both sexes, all ages. 2020; [accessed 13 Sep 2021] Available from: https://gco.iarc.fr/today

2. Ouwens M, Darilay A, Zhang Y, Mukhopadhyay P, Mann H, Ryan J, et al. Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non – Small Cell Lung Cancer from the PACIFIC Study. Current Therapeutic Research, Clinical and Experimental. 2021;95:100640. [accessed 13 Sep 2021] Available from: /pmc/articles/PMC8406163/ 3. Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, et al. Treatment of Stage III Non-small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence Based Clinical Practice Guidelines. CHEST. 2013 May 1;143(5):e314S-e340S. [accessed 9 Nov 2021] Available from: http://journal.chestnet.org/article/S0012369213602998/fulltext

4. Collins LG, Haines C, Perkel R, Enck RE. Lung Cancer: Diagnosis and Management. American Family Physician. 2007 Jan 1;75(1):56 – 63. [accessed 9 Nov 2021] Available from: http://familydoctor.org/161.xml.

5. Adizie JB, Khakwani A, Beckett P, Navani N, West D, Woolhouse I, et al. Stage III Non-small Cell Lung Cancer Management in England. Clinical Oncology. 2019 Oct 1;31(10):688 – 96. doi: 10.1016/J.CLON.2019.07.020

6. de Ruysscher D, Ramalingam S, Urbanic J, Gerber DE, Tan DSW, Cai J, et al. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. Clinical Lung Cancer. 2021 Jul; doi: 10.1016/J.CLLC.2021.07.005 7. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial | Elsevier Enhanced Reader. [accessed 13 Sep 2021] Available from: https://reader.elsevier.com/reader/sd/pii/S1556086421000228?token=FF89262FB9F8B464A4BE649AA10EE5979C8F 8261D9F602B48614AC1669F0B9C5E6DA3BB59A7038A5C53B46600C5AC987&originRegion=eu-west 1&originCreation=20210913074434 8. SE S, SL H, AD T, HJ R, WL M, YA G, et al. Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017 Apr 1;12(4):697 – 703. [accessed 15 Sep 2021] Available from: https://pubmed.ncbi.nlm.nih.gov/28089762/ 9. R R, KE R, E V, LA K, JL F, R N, et al. Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. International journal of radiation oncology, biology, physics. 2004 Nov 1;60(3):741 – 7. [accessed 15 Sep 2021] Available from: https://pubmed.ncbi.nlm.nih.gov/15465190/ 10. S Y, X S, M L, J Y, R R, Y Y, et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. American journal of clinical oncology. 2007 Jun;30(3):239 – 44. [accessed 15 Sep 2021] Available from: https://pubmed.ncbi.nlm.nih.gov/17551299/